Microneedling Outcomes in Early Postsurgical Scars
by Claytor, R. Brannon; Sheck, Casey Gene; Chopra, Vinod
Plastic and Reconstructive Surgery: September
2022 - Volume 150 - Issue 3 - p 557e-561e
Background:
Scars are a vexing sequela of surgery. Microneedling, also
known as minimally invasive percutaneous collagen induction, has demonstrated
impressive improvements in chronic acne scars; however, no evidence exists for
treating postsurgical scars during active wound healing. The purpose of this
study was to demonstrate the utility and safe use of minimally invasive
percutaneous collagen induction in acute postsurgical scars.
Methods:
Twenty-five patients who underwent surgery had scars treated
with three treatments of minimally invasive percutaneous collagen induction in
the postoperative period. Scar assessment was measured by Vancouver Scar Scale,
Patient and Observer Scar Assessment Scale, and Global Aesthetic Improvement
Scale after each of the three treatments and at final 2-month follow-up.
Results:
Patients had positive improvement in Vancouver Scar Scale,
Patient and Observer Scar Assessment Scale, and Global Aesthetic Improvement
Scale scores at 16-week posttreatment initiation evaluation compared to initial
measurement (p < 0.001). No statistically significant differences were
noted when comparing the age of the patient, location of scars, or Fitzpatrick
phototype scales among patients. When comparing patients who began treatment
early (6 to 7 weeks postoperatively) to those who began treatment late (13 to
16 weeks postoperatively), there was a statistically significant difference in
the Patient and Observer Scar Assessment Scale group (p < 0.04).
Conclusions:
Postsurgical scars treated with minimally invasive
percutaneous collagen induction in the maturation and remodeling phase had no
adverse outcomes. Interestingly, the data show treatment initiated early in the
maturation phase (6 to 7 weeks postoperatively), while natural collagen
formation was tapering off, demonstrated improved aesthetic outcomes compared
to treatments initiated late in the maturation phase (13 to 16 weeks
postoperatively).